Pentixapharm Holding AG Shifts Focus to Advanced Clinical Development Programs
Update: 2025-10-23
Description
Pentixapharm Holding AG, a Berlin-based biotech company, is reducing early-stage research activities and implementing a 50 percent reduction in workforce to lower costs and extend cash runway. The company remains dedicated to its Phase 3-ready CXCR4 flagship program for treatment-resistant hypertension, emphasizing the importance of optimizing operational costs to achieve clinical milestones and support sustainable growth in precision diagnostics and therapeutics for oncology and cardiology.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
